Literature DB >> 15991153

Predicting perioperative cardiac risk.

Miklos D Kertai1, Jan Klein, Jeroen J Bax, Don Poldermans.   

Abstract

Cardiovascular complications are the major cause of perioperative morbidity and mortality of patients undergoing major vascular surgery. This is related to the frequent presence of an underlying coronary artery disease. This paper reviews the pathology of perioperative cardiac complications and cardiac risk assessment and risk reduction strategies. Guidelines of the American College of Cardiology and American Heart Association for the evaluation of cardiac risk for noncardiac surgery may provide the necessary framework for the assessment and management of patients undergoing major vascular surgery. Based on the American College of Cardiology and American Heart Association guidelines and data from contemporary studies, patients without risk factors are considered to be at low risk and do not require additional evaluations for coronary artery disease. Patients with 1 or 2 cardiac risk factors represent an intermediate-risk group for perioperative cardiac complications. If beta-blockers are prescribed, the probability of cardiac complications is low and there is no need for further noninvasive testing. Patients with 3 or more risk factors are at high risk for cardiac complications and the use of noninvasive testing may help further refine cardiac risk based on the presence and absence of test-induced myocardial ischemia. beta-Blockers should be prescribed to all patients, and coronary revascularization should be reserved for high-risk patients who have a clearly defined need for revascularization independent of the need for major vascular surgery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15991153     DOI: 10.1016/j.pcad.2005.01.002

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  8 in total

1.  Goal-directed fluid therapy in gastrointestinal surgery in older coronary heart disease patients: randomized trial.

Authors:  Hong Zheng; Hai Guo; Jian-Rong Ye; Lin Chen; Hai-Ping Ma
Journal:  World J Surg       Date:  2013-12       Impact factor: 3.352

2.  Sevoflurane post-conditioning protects isolated rat hearts against ischemia-reperfusion injury via activation of the ERK1/2 pathway.

Authors:  Hong Xie; Jing Zhang; Jiang Zhu; Li-xin Liu; Mario Rebecchi; Su-mei Hu; Chen Wang
Journal:  Acta Pharmacol Sin       Date:  2014-10-27       Impact factor: 6.150

3.  Preoperative evaluation and treatment of stable CAD in patients scheduled for major elective vascular surgery.

Authors:  Rosemary F Kelly; Edward O McFalls
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-02

4.  The SF-36 and 6-Minute Walk Test are Significant Predictors of Complications After Major Surgery.

Authors:  Haitham Awdeh; Kassem Kassak; Pierre Sfeir; Hadi Hatoum; Hala Bitar; Ahmad Husari
Journal:  World J Surg       Date:  2015-06       Impact factor: 3.352

5.  Goal-directed fluid restriction using stroke volume variation and cardiac index during one-lung ventilation: a randomized controlled trial.

Authors:  Hui Xu; Shu-Hua Shu; Di Wang; Xiao-Qing Chai; Yan-Hu Xie; Wei-De Zhou
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

6.  Role of mitochondrial ATP-sensitive potassium channel-mediated PKC-ε in delayed protection against myocardial ischemia/reperfusion injury in isolated hearts of sevoflurane-preconditioned rats.

Authors:  C Wang; S M Hu; H Xie; S G Qiao; H Liu; C F Liu
Journal:  Braz J Med Biol Res       Date:  2015-03-27       Impact factor: 2.590

7.  Regadenoson-Stress Dynamic Myocardial Perfusion Improves Diagnostic Performance of CT Angiography in Assessment of Intermediate Coronary Artery Stenosis in Asymptomatic Patients.

Authors:  Jan Baxa; Milan Hromádka; Jakub Šedivý; Lucie Štěpánková; Jiří Moláček; Bernhard Schmidt; Thomas Flohr; Jiří Ferda
Journal:  Biomed Res Int       Date:  2015-07-05       Impact factor: 3.411

8.  Salvianolic Acid A Ameliorates Arsenic Trioxide-Induced Cardiotoxicity Through Decreasing Cardiac Mitochondrial Injury and Promotes Its Anticancer Activity.

Authors:  Jing-Yi Zhang; Min Wang; Rui-Ying Wang; Xiao Sun; Yu-Yang Du; Jing-Xue Ye; Gui-Bo Sun; Xiao-Bo Sun
Journal:  Front Pharmacol       Date:  2018-05-09       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.